Andy Chen
Stock Analyst at Wolfe Research
(4.64)
# 852
Out of 4,698 analysts
71
Total ratings
68.4%
Success rate
29.7%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andy Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MDGL Madrigal Pharmaceuticals | Upgraded: Buy | $605 | $541.08 | +11.81% | 3 | Aug 4, 2026 | |
| VRTX Vertex Pharmaceuticals | Maintained: Buy | $548 → $557 | $546.12 | +1.99% | 5 | Aug 3, 2026 | |
| SYRE Spyre Therapeutics | Downgraded: Hold | n/a | $88.98 | - | 2 | Jul 28, 2026 | |
| IONS Ionis Pharmaceuticals | Downgraded: Hold | n/a | $58.09 | - | 3 | Jul 15, 2026 | |
| NTLA Intellia Therapeutics | Downgraded: Sell | $9 | $12.74 | -29.36% | 5 | Jul 15, 2026 | |
| SRPT Sarepta Therapeutics | Upgraded: Buy | $27 | $22.50 | +20.00% | 2 | Jul 8, 2026 | |
| CLDX Celldex Therapeutics | Maintained: Buy | $44 | $39.68 | +10.89% | 4 | Jun 14, 2026 | |
| ABVX ABIVAX Société Anonyme | Rated: Buy | $176 → $136 | $114.79 | +18.48% | 2 | Jun 3, 2026 | |
| VERA Vera Therapeutics | Maintained: Buy | $88 | $35.89 | +145.19% | 4 | Jun 2, 2026 | |
| PALI Palisade Bio | Initiated Coverage: Buy | $7 | $2.09 | +234.93% | 1 | Apr 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $48 | $19.23 | +149.61% | 1 | Apr 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $98 | $108.10 | -9.34% | 1 | Apr 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $42 | $35.25 | +19.15% | 1 | Apr 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $47 | $39.25 | +19.75% | 4 | Apr 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $24 | $15.01 | +59.89% | 5 | Mar 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $117.39 | - | 4 | Jan 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $1,033.15 | - | 3 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $13 | $4.78 | +171.97% | 1 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $54 → $173 | $126.29 | n/a | 3 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Hold | n/a | $266.11 | n/a | 4 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $49 | $74.84 | n/a | 1 | Jun 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $25 | $56.80 | n/a | 2 | May 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $84 | $126.75 | n/a | 2 | Mar 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $20 | $92.51 | n/a | 1 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $19 | $32.88 | n/a | 1 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $29 | $22.92 | n/a | 1 | Jun 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $55.79 | n/a | 1 | Feb 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $34.93 | n/a | 1 | Feb 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $4 | $6.79 | n/a | 1 | Oct 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $60 | $0.0001 | n/a | 2 | Aug 10, 2023 |
Madrigal Pharmaceuticals
Aug 4, 2026
Upgraded: Buy
Price Target: $605
Current: $541.08
Upside: +11.81%
Vertex Pharmaceuticals
Aug 3, 2026
Maintained: Buy
Price Target: $548 → $557
Current: $546.12
Upside: +1.99%
Spyre Therapeutics
Jul 28, 2026
Downgraded: Hold
Price Target: n/a
Current: $88.98
Upside: -
Ionis Pharmaceuticals
Jul 15, 2026
Downgraded: Hold
Price Target: n/a
Current: $58.09
Upside: -
Intellia Therapeutics
Jul 15, 2026
Downgraded: Sell
Price Target: $9
Current: $12.74
Upside: -29.36%
Sarepta Therapeutics
Jul 8, 2026
Upgraded: Buy
Price Target: $27
Current: $22.50
Upside: +20.00%
Celldex Therapeutics
Jun 14, 2026
Maintained: Buy
Price Target: $44
Current: $39.68
Upside: +10.89%
ABIVAX Société Anonyme
Jun 3, 2026
Rated: Buy
Price Target: $176 → $136
Current: $114.79
Upside: +18.48%
Vera Therapeutics
Jun 2, 2026
Maintained: Buy
Price Target: $88
Current: $35.89
Upside: +145.19%
Palisade Bio
Apr 8, 2026
Initiated Coverage: Buy
Price Target: $7
Current: $2.09
Upside: +234.93%
Apr 8, 2026
Initiated Coverage: Buy
Price Target: $48
Current: $19.23
Upside: +149.61%
Apr 8, 2026
Maintained: Buy
Price Target: $98
Current: $108.10
Upside: -9.34%
Apr 8, 2026
Initiated Coverage: Buy
Price Target: $42
Current: $35.25
Upside: +19.15%
Apr 6, 2026
Maintained: Buy
Price Target: $47
Current: $39.25
Upside: +19.75%
Mar 23, 2026
Upgraded: Buy
Price Target: $24
Current: $15.01
Upside: +59.89%
Jan 6, 2026
Downgraded: Hold
Price Target: n/a
Current: $117.39
Upside: -
Nov 24, 2025
Downgraded: Hold
Price Target: n/a
Current: $1,033.15
Upside: -
Nov 5, 2025
Initiated Coverage: Buy
Price Target: $13
Current: $4.78
Upside: +171.97%
Aug 14, 2025
Maintained: Buy
Price Target: $54 → $173
Current: $126.29
Upside: n/a
Aug 4, 2025
Upgraded: Hold
Price Target: n/a
Current: $266.11
Upside: n/a
Jun 16, 2025
Initiated Coverage: Buy
Price Target: $49
Current: $74.84
Upside: n/a
May 21, 2025
Reiterated: Buy
Price Target: $25
Current: $56.80
Upside: n/a
Mar 17, 2025
Maintained: Buy
Price Target: $84
Current: $126.75
Upside: n/a
Feb 3, 2025
Initiated Coverage: Buy
Price Target: $20
Current: $92.51
Upside: n/a
Feb 3, 2025
Initiated Coverage: Buy
Price Target: $19
Current: $32.88
Upside: n/a
Jun 10, 2024
Rated: Buy
Price Target: $29
Current: $22.92
Upside: n/a
Feb 14, 2024
Initiated Coverage: Hold
Price Target: n/a
Current: $55.79
Upside: n/a
Feb 14, 2024
Initiated Coverage: Buy
Price Target: n/a
Current: $34.93
Upside: n/a
Oct 25, 2023
Maintained: Buy
Price Target: $4
Current: $6.79
Upside: n/a
Aug 10, 2023
Reiterated: Buy
Price Target: $60
Current: $0.0001
Upside: n/a